countries · sectors · sub-national hubs · trade bodies · FTAs · tools · academy · essays
USD 8.5B/yr India export
Not just bilateral India↔EU. AJG brokers all directions — Unilateral, Bilateral, Trilateral, Multilateral. Each route below is an active mandate configuration we work across both principals.
v129.1 · vertical-deep-data · pharma
India is the world' largest generic pharmaceutical exporter and the EU is its largest pharma market by value. This SOP covers the complete pathway from Indian WHO-GMP facility to EU-licensed finished dose or API supply — EU GMP certification, EDQM CEP filing, marketing authorisation, export documentation, and pharmacovigilance obligations.…
End-to-end pathway for Pharma exports from India to Netherlands. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipme…
End-to-end pathway for Pharma exports from India to Spain. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment com…
End-to-end pathway for Pharma exports from India to UAE. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment compl…
End-to-end pathway for Pharma exports from India to Taiwan. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment co…
End-to-end pathway for Pharma exports from India to Argentina. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment…
End-to-end pathway for Pharma exports from India to New Zealand. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipme…
End-to-end pathway for Pharma exports from India to Canada. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment co…
End-to-end pathway for Pharma exports from India to Brazil. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment co…
End-to-end pathway for Pharma exports from India to Philippines. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipme…
End-to-end pathway for Pharma exports from India to Malaysia. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment …
End-to-end pathway for Pharma exports from India to Chile. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment com…
End-to-end pathway for Pharma exports from India to Vietnam. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment c…
End-to-end pathway for Pharma exports from India to Mexico. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment co…
End-to-end pathway for Pharma exports from India to Italy. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment com…
End-to-end pathway for Pharma exports from India to Poland. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment co…
End-to-end pathway for Pharma exports from India to South Korea. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipme…
End-to-end pathway for Pharma exports from India to Thailand. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment …
End-to-end pathway for Pharma exports from India to Colombia. Covers regulatory pathway selection (EU GMP / FDA 21 CFR 211 / WHO-GMP), certifications stack, export documentation (commercial invoice, packing list, certificate of origin, B/L, insurance certificate), Incoterm-aligned pricing, payment mechanics, lead-time management, and post-shipment …
Challenge: A mid-sized Hyderabad-based API manufacturer had WHO-GMP certification and was supplying Indian domestic pharma companies. They identified a EUR 8M annual opportunity with a German generics manufacturer who required EU GMP-certified API facilities. The manufacturer had no EU GMP certification, no CEP from EDQM, and no familiarity with the EU regulatory pathway. They estimated the entire qualificat…
Outcome: EU GMP certificate obtained at month 19. EDQM CEP granted at month 22. First commercial EU shipment at month 24. Annual EU contract value: EUR 8.2 million. ECGC Standard Policy secured for the German buyer relationship. RoDTEP benefit on API exports calculated at 2.1% of FOB value.…
Challenge: A Mumbai-based generic pharmaceutical company wanted to export finished dose tablets to EU but had no EU marketing authorisation (MA). They had approached two EU regulatory consultants who quoted EUR 500,000 and 5 years for a centralised EMA procedure. The company needed a faster, more capital-efficient market entry route.…
Outcome: First EU shipment completed within 14 months of mandate commencement. Indian manufacturer generates EUR 2.8M annually from EU supply under the licensing arrangement. The Dutch partner handles MA maintenance, EU pharmacovigilance, and distribution. Indian manufacturer now investing in their own EU MA for 3 products using profits from the licensing income.…
Challenge: A Gujarat-based API manufacturer had been exporting to Germany for 3 years under standard MFN tariff and not claiming RoDTEP or any GSP preference. Annual exports were EUR 5M. The company was unaware that their specific API HS codes qualified for EU GSP preferences and RoDTEP, and was leaving significant money unclaimed.…
Outcome: Annual EU GSP duty saving: EUR 85,000 (shared value between Indian exporter price reduction and German buyer duty saving). RoDTEP annual benefit: INR 1.8 crore (approximately USD 215,000). Total annual combined benefit: approximately USD 340,000. Investment: PHARMEXCIL RCMC (INR 15,000/year) plus COO issuance cost (INR 1,200 per shipment).…
Challenge: A Pune-based generic pharma company had been supplying a Spanish pharma distributor on 60-day open account terms for 2 years. The relationship was established, and the Indian exporter had not taken ECGC cover. The Spanish distributor entered insolvency proceedings in April 2025. Outstanding receivables from the Indian exporter were USD 280,000 across 4 unpaid invoices.…
Outcome: ECGC claim settled: USD 140,000 (50% of USD 280,000 outstanding). Spanish insolvency proceedings estimated to return 15-20 cents on the dollar — expected additional recovery USD 42,000-56,000. Total expected recovery: approximately USD 182,000-196,000 of USD 280,000 outstanding. Exporter has since obtained ECGC Standard Policy for all EU buyers.…
The India-EU Free Trade Agreement has been in negotiation since 2007 with a relaunch in 2022 and a target conclusion in 2026. When concluded, it will eliminate duties on 90%+ of goods and open the EU single market of 450…
The India-UAE Comprehensive Economic Partnership Agreement entered force on 1 May 2022. Two years into implementation, bilateral trade has grown significantly but utilisation of CEPA preferential rates remains below pote…
India supplies approximately 20% of global generic medicines by volume and the EU is India largest pharmaceutical export destination. With India-EU FTA negotiations advancing and EU drug pricing pressures intensifying, t…
Rules of Origin are the gateway to FTA benefits and the most commonly misunderstood element of international trade. This guide explains the three main RoO criteria, provides worked examples for key India verticals, and g…
The latest India-EU FTA negotiating round shows substantive progress on tariff schedules with IP and government procurement remaining the two outstanding issues…
EU governments have implemented explicit policies to diversify pharmaceutical supply chains away from China. AJG analysis shows India is capturing significant E…
India-UK FTA negotiations have 23 of 28 chapters agreed. Five sensitive chapters remain: Mode 4 visas, Scotch whisky tariff, automotive, dairy, and government p…
The Netherlands handles 40% of all India-EU container trade through Rotterdam. But India-Netherlands is also a USD 18B bilateral in its own right — with uniqu…
Explore
Every page in the AJG platform cross-links to these primary entities. Click any pill to explore that branch of the knowledge graph.